Business Wire, "Lucira Health Announces Pricing of Its Upsized Initial Public Offering"

Summary

A Business Wire press release from Lucira Health, Inc. of Emeryville, Calif., announcing the pricing of its upsized initial public offering of 9,000,000 shares of common stock at $17.00 per share. It states expected gross proceeds of $153.0 million before underwriting discounts, commissions and offering expenses, and a 30-day underwriter option on up to an additional 1,350,000 shares. The shares were expected to begin trading on the Nasdaq Global Select Market under the symbol LHDX on February 5, 2021, with closing expected on February 9, 2021. BofA Securities and William Blair are named as lead bookrunning managers, and the release describes the LUCIRA COVID-19 All-In-One Test Kit.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

-

Lucira Health Announces Pricing of Its Upsized Initial Public Offering

Share

EMERYVILLE, Calif.--( BUSINESS WIRE )-- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced the pricing of its upsized initial public offering of 9,000,000 shares of common stock at a price to the public of $17.00 per share. The gross proceeds to Lucira from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $153.0 million. In addition, Lucira has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock, at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “LHDX” on February 5, 2021. The offering is expected to close on February 9, 2021, subject to satisfaction of customary closing conditions.

BofA Securities and William Blair are acting as lead bookrunning managers and LifeSci Capital is acting as co-manager for the offering.

The offering is being made only by means of a prospectus. When available, a copy of the final prospectus may be obtained from: BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, or by telephone at (800) 294-1322, or by email at dg.prospectus_requests@bofa.com , or William Blair, Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by telephone at (800) 621-0687 or email at prospectus@williamblair.com .

Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on February 4, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Lucira Health

Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand. Lucira designed its test kits to provide accurate, reliable and on-the-spot molecular test results anywhere and at any time. The LUCIRA COVID-19 All-In-One Test Kit is designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection.

Contacts

Media Relations Kevin Knight media@lucirahealth.com 206-451-4823

Investor Relations Jeremy Feffer Jeremy@lifesciadvisors.com 212-915-2568

Industry:

Lucira Health, Inc.

NASDAQ:LHDX

Release Versions

English

Contacts

Media Relations Kevin Knight media@lucirahealth.com 206-451-4823

Investor Relations Jeremy Feffer Jeremy@lifesciadvisors.com 212-915-2568

More News From Lucira Health, Inc.

LUCIRA™ HEALTH Hires Ghazi Kashmolah as Chief Quality Officer and EVP Regulatory Affairs

EMERYVILLE, Calif.--( BUSINESS WIRE )--Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced life science professional Ghazi Kashmolah has joined the company as Chief Quality Officer and Executive Vice President Regulatory Affairs. “Ghazi is a strong addition to Lucira’s executive leadership team, and we are delighted to have him...

LUCIRA™ HEALTH Hires Chief Revenue Officer Kevin Collins

EMERYVILLE, Calif.--( BUSINESS WIRE )--Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced medtech veteran Kevin Collins has joined the company as Chief Revenue Officer with global revenue responsibility. Collins began his medical technology career with Lumenis Ltd., a medical equipment and laser technologies company, where he rose from Area Sales Manager to...

LUCIRA™ CHECK IT COVID-19 Self-Test Now Available on Amazon

EMERYVILLE, Calif.--( BUSINESS WIRE )--Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that its LUCIRA™ CHECK IT COVID-19 test kit is now available on Amazon.com in the US. Each LUCIRA CHECK IT test kit provides a PCR quality test result at home in 30 minutes or less. After testing, users can also receive a free, text based digital LUCI PASS verified tes...

Back to Newsroom

Lucira Health, Inc.

NASDAQ:LHDX

Release Versions

English

Contacts

Media Relations Kevin Knight media@lucirahealth.com 206-451-4823

Investor Relations Jeremy Feffer Jeremy@lifesciadvisors.com 212-915-2568

File and source

File

lucira-health-announces-pricing-of-its-upsized-initial-public-offering_b9d83e3daf30a65b.html

Size

364,253 bytes

SHA-256

966da9bf9d975bf89dbe7bce24f9360561feb6bf47890e8fe5b37d019c57c876

Our copy

lucira-health-announces-pricing-of-its-upsized-initial-public-offering_b9d83e3daf30a65b.html

Original

www.businesswire.com